Literature DB >> 17951207

miRNA: the new gene silencer.

Jeffrey S Ross1, J Andrew Carlson, Graham Brock.   

Abstract

MicroRNAs (miRNAs) can be defined as small, noncoding sets of 19 to 24 nucleotides that have been associated with messenger RNA expression. miRNAs are members of a class of small regulatory RNAs that includes small interfering RNAs (siRNAs). miRNAs regulate the expression of downstream gene targets, including transcription factors, oncogenes, and tumor suppressor genes. Transcriptional profiling using genomic microarrays and beads has enabled the discovery of numerous miRNAs that are differentially expressed in normal tissues vs tumors and associated with cancer development, diagnosis, and prognosis. miRNA signatures can be used to detect and classify cancer and predict the severity of disease, with certain profiles of miRNA expression linked to aggressive cancers with advanced disease present at diagnosis. miRNAs have also become targets of novel anticancer gene therapy with antisense molecules that can inhibit miRNA activity currently being tested for their efficacy in a strategy of reducing miRNA activity on reporter genes bearing miRNA-binding sites. In the future, sophisticated genomic and proteomic techniques combined with complex bioinformatics data analyses will be required to translate these recent basic science discoveries to clinically useful diagnostic tests.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17951207     DOI: 10.1309/2JK279BU2G743MWJ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  33 in total

Review 1.  Evidence demonstrating role of microRNAs in the etiopathology of major depression.

Authors:  Yogesh Dwivedi
Journal:  J Chem Neuroanat       Date:  2011-04-14       Impact factor: 3.052

2.  Lentivirus-mediated RNA silencing of c-Met markedly suppresses peritoneal dissemination of gastric cancer in vitro and in vivo.

Authors:  Xiao-lei Wang; Xi-mei Chen; Jian-ping Fang; Chang-qin Yang
Journal:  Acta Pharmacol Sin       Date:  2012-03-12       Impact factor: 6.150

3.  Measuring circulating miRNAs: the new "PSA" for Breast Cancer?

Authors:  Jeffrey S Ross
Journal:  Oncologist       Date:  2010-06-28

Review 4.  Hepatitis viruses and non-Hodgkin's lymphoma: A review.

Authors:  Sibnarayan Datta; Soumya Chatterjee; Rudragoud S Policegoudra; Hemant K Gogoi; Lokendra Singh
Journal:  World J Virol       Date:  2012-12-12

Review 5.  miRNAs: novel regulators of autoimmunity-mediated pancreatic β-cell destruction in type 1 diabetes.

Authors:  Ying Zheng; Zhen Wang; Zhiguang Zhou
Journal:  Cell Mol Immunol       Date:  2017-03-20       Impact factor: 11.530

6.  Decreased expression of microRNA-206 correlates with poor clinical outcome in patients with malignant astrocytomas.

Authors:  Shuai Wang; Shengkui Lu; Shaomei Geng; Shucheng Ma; Zhaohui Liang; Baohua Jiao
Journal:  Pathol Oncol Res       Date:  2014-01-05       Impact factor: 3.201

7.  Intracellular MicroRNA Quantification in Intact Cells: A Novel Strategy based on Reduced Graphene Oxide Based Fluorescence Quenching.

Authors:  Ramasamy Paulmurugan; Pulickel M Ajayan; Dorian Liepmann; V Renugopalakrishnan
Journal:  MRS Commun       Date:  2018-07-13       Impact factor: 2.566

Review 8.  MET as a target for treatment of chest tumors.

Authors:  Nicole A Cipriani; Oyewale O Abidoye; Everett Vokes; Ravi Salgia
Journal:  Lung Cancer       Date:  2008-07-30       Impact factor: 5.705

Review 9.  Translation regulation of mRNAs by the fragile X family of proteins through the microRNA pathway.

Authors:  Anne Cheever; Stephanie Ceman
Journal:  RNA Biol       Date:  2009-04-17       Impact factor: 4.652

10.  Differential micro RNA expression in PBMC from multiple sclerosis patients.

Authors:  David Otaegui; Sergio E Baranzini; Ruben Armañanzas; Borja Calvo; Maider Muñoz-Culla; Puya Khankhanian; Iñaki Inza; Jose A Lozano; Tamara Castillo-Triviño; Ana Asensio; Javier Olaskoaga; Adolfo López de Munain
Journal:  PLoS One       Date:  2009-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.